Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. The company provides prescription drugs for anti-hypertension, anti-hyperlipidemia, anti-diabetics, and immunosuppressants; over-the-counter medicine comprising headache remedies, dewormers, digestive aids, and vitamins; probiotics and Omega-3 supplements; and he… Read more
Chong Kun Dang Pharmaceutical (185750) - Total Assets
Latest total assets as of September 2025: ₩1.52 Trillion KRW
Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) holds total assets worth ₩1.52 Trillion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chong Kun Dang Pharmaceutical - Total Assets Trend (2016–2024)
This chart illustrates how Chong Kun Dang Pharmaceutical’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Chong Kun Dang Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Chong Kun Dang Pharmaceutical's total assets of ₩1.52 Trillion consist of 66.0% current assets and 34.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 15.7% |
| Accounts Receivable | ₩266.74 Billion | 18.3% |
| Inventory | ₩353.84 Billion | 24.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩75.64 Billion | 5.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Chong Kun Dang Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chong Kun Dang Pharmaceutical's current assets represent 66.0% of total assets in 2024, an increase from 52.8% in 2016.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2024, up from 3.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 24.3% of total assets.
Chong Kun Dang Pharmaceutical Competitors by Total Assets
Key competitors of Chong Kun Dang Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Chong Kun Dang Pharmaceutical - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Chong Kun Dang Pharmaceutical generates 1.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Chong Kun Dang Pharmaceutical generates $7.48 in net profit.
Chong Kun Dang Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.89 | 2.54 | 1.87 |
| Quick Ratio | 1.02 | 1.66 | 1.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩409.91 Billion | ₩ 596.71 Billion | ₩ 279.49 Billion |
Chong Kun Dang Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Chong Kun Dang Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.31 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | ₩1.46 Trillion |
| Market Capitalization | $464.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chong Kun Dang Pharmaceutical's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Chong Kun Dang Pharmaceutical's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Chong Kun Dang Pharmaceutical (2016–2024)
The table below shows the annual total assets of Chong Kun Dang Pharmaceutical from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.46 Trillion | +4.02% |
| 2023-12-31 | ₩1.40 Trillion | +24.67% |
| 2022-12-31 | ₩1.12 Trillion | +7.47% |
| 2021-12-31 | ₩1.05 Trillion | +10.61% |
| 2020-12-31 | ₩946.33 Billion | +18.09% |
| 2019-12-31 | ₩801.35 Billion | +12.63% |
| 2018-12-31 | ₩711.49 Billion | +5.06% |
| 2017-12-31 | ₩677.21 Billion | +5.53% |
| 2016-12-31 | ₩641.70 Billion | -- |